Seminars in Hematology
Volume 41, Issue 1 , Pages 41-47 , January 2004

Assays of ADAMTS-13 activity

  • Agnès Veyradier

      Affiliations

    • INSERM U.143, Hôpital de Bicêtre, Paris, France
    • ,
  • Jean-Pierre Girma

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jean-Pierre Girma, INSERM U.143, 84 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre, France
    • INSERM U.143, Hôpital de Bicêtre, Paris, France

References 

  1. Pimanda J, Hogg P. Control of von Willebrand factor multimer size and implications for disease. Blood Rev. 2002;16:185–192
  2. Siedlecki CA, Lestini BJ, Kottke-Marchant K, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939–2950
  3. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83:2171–2179
  4. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–4234
  5. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235–4244
  6. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type-IIA von Willebrand disease mutations. J Biol Chem. 1992;267:4424–4430
  7. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q (Inhibition by doxycycline and by monoclonal antibody VP-1). Blood. 1997;89:1954–1962
  8. Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJW, Bracke M, Furlan M, et al.  Recombinant vWF type 2A mutants R834Q and R834W show a defect in mediating platelet adhesion to collagen, independent of enhanced sensitivity to a plasma protease. Thromb Haemost. 1999;81:976–983
  9. Zheng XL, Chung D, Takayama TK, Majerus EM, Salder JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063
  10. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103
  11. Allford SL, Harrison P, Lawrie AS, Liesner R, Mackie IJ, Machin SJ. von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol. 2000;111:1215–1222
  12. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, et al.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798–3802
  13. Krizek DM, Rick ME. Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity. Electrophoresis. 2001;22:946–949
  14. Krizek DR, Rick ME. A rapid method to visualize von Willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res. 2000;97:457–462
  15. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  16. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662–1666
  17. Girma JP, Chopek MW, Titani K, Davie EW. Limited proteolysis of human von Willebrand Factor by staphylococcus aureus V-8 protease (Isolation and partial characterization of a platelet-binding domain). Biochemistry. 1986;25:3156–3163
  18. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF—A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386–1389
  19. Aronson DL, Krizek DM, Rick ME. A rapid assay for the vWF protease. Thromb Haemost. 2001;85:184–185
  20. Rick ME, Moll S, Taylor MA, Krizek DM, White GC, Aronson DL. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2002;88:598–604
  21. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, et al.  von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 2003;101:1845–1850
  22. Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol. 2002;81:430–435
  23. Yoo G, Blomback M, Schenck-Gustafsson K, He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura (study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation). Br J Haematol. 2003;121:123–129
  24. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M, et al.  Upshaw-Schulman syndrome revisited (A concept of congenital thrombotic thrombocytopenic purpura). Int J Hematol. 2001;74:101–108
  25. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost. 1999;82:1382–1385
  26. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies (A study of 111 cases). Blood. 2001;98:1765–1772
  27. Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839–2846
  28. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al.  Proceedings (A more uniform measurement of factor VIII inhibitors). Thromb Diath Haemorrh. 1975;34:612
  29. Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab. 2001;47:387–392
  30. Park YD, Yoshioka A, Kawa K, Ishizashi H, Yagi H, Yamamoto Y, et al.  Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant. 2002;29:789–794
  31. Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, et al.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–580
  32. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lammle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma (A multicenter comparison of different assay methods). J Thromb Haemost. 2003;1:1882–1887

PII: S0037-1963(03)00270-1

doi: 10.1053/j.seminhematol.2003.10.005

Seminars in Hematology
Volume 41, Issue 1 , Pages 41-47 , January 2004

Article Tools

* Image Usage & Resolution